GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (FRA:4DY) » Definitions » Capex-to-Revenue

4d pharma (FRA:4DY) Capex-to-Revenue : 0.30 (As of Dec. 2021)


View and export this data going back to 2020. Start your Free Trial

What is 4d pharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

4d pharma's Capital Expenditure for the six months ended in Dec. 2021 was €-0.10 Mil. Its Revenue for the six months ended in Dec. 2021 was €0.34 Mil.

Hence, 4d pharma's Capex-to-Revenue for the six months ended in Dec. 2021 was 0.30.


4d pharma Capex-to-Revenue Historical Data

The historical data trend for 4d pharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Capex-to-Revenue Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Capex-to-Revenue
Get a 7-Day Free Trial - - 2.80 0.33 0.39

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 0.63 0.01 0.50 0.30

Competitive Comparison of 4d pharma's Capex-to-Revenue

For the Biotechnology subindustry, 4d pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4d pharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where 4d pharma's Capex-to-Revenue falls into.



4d pharma Capex-to-Revenue Calculation

4d pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.239) / 0.614
=0.39

4d pharma's Capex-to-Revenue for the quarter that ended in Dec. 2021 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.102) / 0.341
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4d pharma  (FRA:4DY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


4d pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of 4d pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma (FRA:4DY) Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (FRA:4DY) Headlines

No Headlines